Tenet Healthcare Corporation stocks have been trading up by 17.45 percent after strong earnings and improved healthcare demand outlook.
Click Here for a Millionaire's POV on Trading THC
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Market Insights For THC Traders
- Q2 2026 adjusted EPS of $6.12 crushed the $4.26 consensus on revenue of $5.63B, showing strong execution and clear upside surprise.
- Net income nearly tripled in Q2 and adjusted EPS rose 52%, powered by higher same-facility revenue, better hospital margins, and solid ambulatory growth.
- Management lifted FY26 guidance to adjusted EPS of $20.30–$21.69 and raised outlooks for revenue, EBITDA, and free cash flow, signaling confidence in continued momentum.
- A $2.0B increase in share repurchase authorization, on top of $1.04B bought back, leaves $2.13B for future buybacks that can support the stock.
- Major banks kept Overweight/Buy ratings on Tenet Healthcare Corporation with price targets in the low-to-mid $230s, despite broader sector worries about Medicaid and valuation multiples.
Weekly Update Jul 20 – Jul 24, 2026: On Friday, July 24, 2026 Tenet Healthcare Corporation stock [NYSE: THC] is trending up by 17.45%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
Tenet Healthcare (THC) is executing from a position of clear strength within U.S. hospital and ambulatory services. Revenue of ~$21.3B with mid‑teens three‑year CAGR, 18.6% EBIT margin and 22.8% EBITDA margin places it at the top end of the hospital peer set on profitability. ROE near 38% and FCF of ~$1.46B vs. enterprise value ~$27.4B (EV/FCF ~19x; P/FCF ~2.5x) underscore capital efficiency, though leverage remains elevated (total debt/equity 2.7x, interest coverage 5.9x).
Technically, THC is in a powerful uptrend, with the weekly sequence from ~$194 to $234 showing successive higher highs and a major breakout day (199 → intraday 233, close 224) confirmed by follow‑through to 234.21 on strong volume. Intraday 5‑minute action shows tight consolidations being bought quickly, indicating institutional accumulation. The key actionable level is $224: above it, longs are favored with upside toward $245; a close below $224 signals risk of a pullback toward $210.
More Breaking News
- MOBX Slides As Weak Financials Weigh On Price Action
- Lockheed Martin Stock Jumps As Long-Term Defense Contracts Pile Up
- Tenet Healthcare Surges As Earnings Beat Fuels Guidance Hike
- AMIX Drops As Warrant Inducement Raises Dilution Fears
Fundamentally, Q2 2026 was a step‑function up in earnings power: adjusted EPS +52%, revenue beat, hospital margins expanding, and guidance raised materially (FY26 EPS $20.30–21.69 vs prior consensus $17.85). Expanded $2B buyback (>$2.1B remaining) and robust FCF compare favorably to Healthcare and Providers & Services peers, where payor‑mix uncertainty and weaker beats dominate. I assign a constructive outlook with a 6–12 month price target of $245, with support at $210 and resistance near $240–245.
Quick Financial Overview
Tenet Healthcare Corporation is backing its strong Q2 2026 story with real numbers. Revenue over the last year is roughly $21.31B, and Q2 alone delivered $5.63B, ahead of expectations. Profitability metrics are solid for a hospital operator: EBIT margin sits near 18.6%, EBITDA margin around 22.8%, and total profit margin close to 7.9%. For traders, that means Q2 was not a one-off headline, but part of a broader trend of improving operating leverage.
The earnings beat was decisive. Adjusted EPS of $6.12 dwarfed consensus at $4.26 and also improved from $4.02 a year ago. Management raised full-year EPS guidance to $20.30–$21.69 and bumped EBITDA and free cash flow guidance higher by about $295M and $225M, respectively. Free cash flow of roughly $1.46B in the latest quarter, against an enterprise value near $27.38B and a price-to-free-cash multiple around 2.5, shows why Tenet Healthcare Corporation feels comfortable leaning into buybacks.
On the tape, THC is confirming the fundamentals. Weekly data show the stock jumping from the mid-$190s early in the week to close around $234.21, a powerful post-earnings expansion. Intraday action shows high volatility but firm demand, with strong buying off the open near $235, a push into the mid-$240s, and steady two-way trade above $230 for most of the session. A trailing P/E near 9.2 and price-to-sales of about 0.72 suggest the market is still pricing in some risk from leverage and payer mix, despite robust returns on equity above 37%.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.